AstraZeneca entered the next-gen obesity race late and is moving through Phase 2b with a multi-asset strategy. The February 2026 $1.2 billion CSPC Pharmaceuticals collaboration brought in the two molecules that anchor the ASCEND program: AZD9550 (GLP-1 + glucagon dual agonist) and AZD6234 (selective amylin analog). Combined as a two-molecule fixed-dose combination, ASCEND is positioned as a 'triple mechanism' targeting fat-selective weight loss and organ protection — the safety-and-organ-protection lane that competitors leave open.
The broader obesity portfolio also includes eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 licensed from Eccogene that met primary endpoints in two Phase 2b trials — VISTA in 310 obesity patients (26-week weight loss) and SOLSTICE in 406 type-2 diabetes patients (26-week HbA1c versus semaglutide). AstraZeneca held back exact weight-loss numbers at the April 29 Q1 print, framing the molecule as 'very competitive,' with full data scheduled for ADA 2026 in June and a comprehensive Phase 3 program now committed. Macrocyclic peptide platform deals — including the early-2025 Syneron Bio collaboration worth up to $3.4 billion in milestones — extend the company's peptide-discovery footprint.
Stories here cover trial readouts, partnership economics, and the broader late-mover obesity strategy. See #azd9550, #azd6234, and #ascend.
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares extended a roughly 30% selloff since the Thursday July 30, 2026 Q2 2026 earnings report, losing approximately $12 billion in market capitalization over the intervening days. The selloff reflects two consecutive negative signals for the RNAi therapeutics leader: the July 30 Amvuttra (vutrisiran, the TTR-directed siRNA that crossed $1 billion in quarterly revenue for the first time at $1.012 billion) full-year 2026 TTR product sales guidance cut to $4.2-4.5 billion (down from prior higher expectations) to reflect normalized second-line volume after the initial pent-up demand from patients waiting for a new therapy, combined with the July AstraZeneca-Ionis eplontersen (Wainua, antisense oligonucleotide) Phase 3 CARDIO-TTRansform study setback that complicates the broader ATTR-CM competitive landscape. The Amvuttra franchise has been positioned as the primary siRNA alternative to Pfizer's Vyndaqel/Vyndamax (tafamidis, small-molecule TTR stabilizer) and BridgeBio's Attruby (acoramidis, next-generation TTR stabilizer). Alnylam presents full eplontersen study data at a late-August medical meeting; analysts flagged the timing as a continued overhang until the presentation clarifies the ATTR-CM segment dynamics. Analyst commentary described the combination as a 'one-two punch' for the company.
President Trump's Section 232 pharmaceutical tariffs took effect Friday July 31, 2026 for the 17 companies named in the initial tranche of the Section 232 national-security investigation. The Section 232 pathway allows the President to impose tariffs on imports that threaten national security; the pharmaceutical investigation was announced April 1, 2025 by the Commerce Department under the Trump administration and formally initiated April 30, 2026. Companies in the initial tranche face tariffs on active pharmaceutical ingredient (API) and finished-drug imports depending on manufacturing-location documentation; the broader pharmaceutical industry faces a September 29 deadline for additional tariff applicability. Peptide-and-obesity-relevant sponsors including Novo Nordisk (Wegovy/Ozempic semaglutide, primarily manufactured in Denmark), Eli Lilly (Zepbound/Mounjaro tirzepatide and Foundayo orforglipron, primarily manufactured in Ireland and Indiana), Merck (LIPFENDRA/enlicitide macrocyclic peptide PCSK9, manufacturing across US and Ireland), AstraZeneca (elecoglipron and biologics portfolio), Sanofi (Dupixent dupilumab), AbbVie (Skyrizi and Rinvoq), Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen all face potential 25% import duties depending on manufacturing-location documentation. President Trump also announced Tuesday July 21 that imported generic drugs would face zero tariffs for two years starting August 2028, providing a two-year runway before generic tariffs begin.
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.
AstraZeneca and Ionis Pharmaceuticals announced Thursday July 9, 2026 that the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen) did not meet its primary efficacy endpoint in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial enrolled over 1,400 patients and was the largest Phase 3 study conducted in the ATTR-CM population to date; the primary endpoint was a composite of cardiovascular mortality and recurrent CV clinical events through 140 weeks compared with placebo. Prespecified subgroup analyses showed nominally significant reductions in composite events with eplontersen monotherapy versus placebo, while patients also receiving a baseline TTR stabilizer showed no incremental effect. Eplontersen is an antisense oligonucleotide (a nucleic-acid therapeutic modality distinct from peptides but adjacent in the metabolic-and-cardiovascular therapeutic territory this site tracks); the drug is already FDA-approved as Wainua for hereditary transthyretin amyloidosis polyneuropathy. Full CARDIO-TTRansform results will be presented at the European Society of Cardiology (ESC) Congress in August 2026. AstraZeneca and Ionis shares fell on the readout.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
AstraZeneca presented VISTA Phase 2b data at ADA 2026 with simultaneous Lancet publication. In adults with obesity or overweight plus comorbidity, oral elecoglipron 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, continuing to 11.8% by 36 weeks, alongside blood-pressure and inflammation reductions. The companion SOLSTICE T2D trial showed 1.9-point HbA1c reductions with 90% reaching HbA1c under 7% and 7.7% weight loss. AstraZeneca announced an extensive Phase 3 program covering obesity, T2D, and cardiovascular and kidney outcome trials.
Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.
Eccogene and AstraZeneca will present multiple datasets for the oral small-molecule GLP-1 receptor agonist elecoglipron (AZD5004/ECC5004) at ADA 2026 on June 7-8, including a late-breaking Phase 1b study conducted in China, plus the Phase 2b VISTA trial in obesity (which met its primary endpoints) and the SOLSTICE Phase 2b trial in type 2 diabetes. The slate deepens the oral-GLP-1 contest forming below Lilly's orforglipron.
Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.
AstraZeneca's eleglipron (formerly elecoglipron / AZD5004 / ECC5004), the oral small-molecule GLP-1 agonist licensed from Eccogene in 2023, met primary endpoints in two Phase 2b trials with results detailed at the company's April 29 Q1 print: VISTA (NCT06579092, 310 obesity patients, 26-week weight loss) and SOLSTICE (NCT06579105, 406 type-2 diabetes patients, 26-week HbA1c change vs semaglutide and placebo). AstraZeneca held back exact weight-loss numbers, framing the molecule as 'very competitive,' with full data scheduled for the American Diabetes Association meeting in June. The company committed to a comprehensive Phase 3 program targeting both weight-loss efficacy and outcome benefits, with monotherapy and fixed-dose combination programs anchored against the SYH2082 dual-agonist and LiquidGel monthly-dosing platform from the $18.5B CSPC Pharmaceuticals collaboration.
AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.